Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRA1 | P14867 | 6/20 | 0.46 |
| ▸ | GABRB1 | P18505 | 4/20 | 0.46 |
| ▸ | GABRB2 | P47870 | 4/20 | 0.44 |
| ▸ | LMNA | P02545 | 3/20 | 0.44 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.44 |
| ▸ | HTR2B | P41595 | 2/20 | 0.44 |
| ▸ | CA1 | P00915 | 2/20 | 0.44 |
| ▸ | CA2 | P00918 | 2/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.44 |
| ▸ | FAAH | O00519 | 1/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.44 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.44 |
| ▸ | HTR2C | P28335 | 1/20 | 0.44 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.44 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.44 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.44 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17444805 | 0.80 | GABRA1 (0.45) | GABRA1GABRB1GABRB2LMNASLC6A2 | |
| SCHEMBL487169 | 0.78 | GABRA1 (0.56) | GABRA1GABRB1GABRB2LMNASLC6A2 | |
| SCHEMBL15553081 | 0.76 | LMNA (0.47) | GABRA1GABRB1GABRB2LMNASLC6A2 | |
| SCHEMBL13748939 | 0.75 | CA1 (0.44) | GABRA1GABRB1GABRB2LMNASLC6A2 | |
| SCHEMBL6015493 | 0.74 | GABRA1 (0.46) | GABRA1GABRB1GABRB2LMNASLC6A2 | |
| SCHEMBL15011592 | 0.74 | LMNA (0.50) | GABRA1GABRB1GABRB2LMNASLC6A2 | |
| SCHEMBL20711666 | 0.74 | LMNA (0.41) | GABRA1GABRB1GABRB2LMNASLC6A2 | |
| SCHEMBL11850416 | 0.74 | ADRB2 (0.39) | LMNACYP3A4CYP1A2TSHRBLM | |
| Hydrochloric Acid SCHEMBL11842180 | 0.73 | ADRB2 (0.38) | LMNACYP3A4CYP1A2TSHRBLM | |
| SCHEMBL11850533 | 0.73 | ADRB1 (0.68) | LMNACYP3A4CYP1A2HPGDTSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230287009-A1 | OXO-SUBSTITUTED COMPOUND | Sumitomo Pharma Co., Ltd. (JP) | 2023-09-14 | — | — | US | disclosed |
| US-11702431-B2 | Oxo-substituted compound | Sumitomo Pharma Co., Ltd. (JP) | 2023-07-18 | — | — | US | disclosed |
| US-20230038124-A1 | NOVEL SUBSTITUTED CONDENSED RING COMPOUND | Sumitomo Pharma Co., Ltd. (JP) | 2023-02-09 | — | — | US | disclosed |
| US-20220162209-A1 | SALICYL-ADENOSINEMONOSULFAMATE ANALOGS AND USES THEREOF | MEMORIAL SLOAN-KETTERING CANCER CENTER (US) | 2022-05-26 | — | — | US | disclosed |
| US-11066425-B1 | Oxo-substituted compound | SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) | 2021-07-20 | — | — | US | disclosed |
| US-10174053-B2 | 2 substituted cephem compounds | GLAXO GROUP LIMITED (GB) | 2019-01-08 | — | — | US | disclosed |
| US-20180186814-A1 | TRICYCLIC COMPOUND HAVING SULFINYL OR SULFONYL | SHIONOGI & CO., LTD. (JP) | 2018-07-05 | — | — | US | disclosed |
| US-20180186814-A1 | TRICYCLIC COMPOUND HAVING SULFINYL OR SULFONYL | SHIONOGI & CO., LTD. (JP) | 2018-07-05 | — | — | US | disclosed |
| US-20170281532-A1 | 2 SUBSTITUTED CEPHEM COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2017-10-05 | — | — | US | disclosed |
| US-20170281532-A1 | 2 SUBSTITUTED CEPHEM COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2017-10-05 | — | — | US | disclosed |
| US-9334289-B2 | Cephem compound having catechol or pseudo-catechol structure | SHIONOGI & CO., LTD. (JP) | 2016-05-10 | — | — | US | disclosed |
| US-9290515-B2 | Cephem derivative having catechol group | SHIONOGI & CO., LTD (JP) | 2016-03-22 | — | — | US | disclosed |
| US-9242999-B2 | Cephem compound having pyridinium group | SHIONOGI & CO., LTD. (JP) | 2016-01-26 | — | — | US | disclosed |
| US-9238657-B2 | Cephalosporin having catechol group | SHIONOGI & CO., LTD. (JP) | 2016-01-19 | — | — | US | disclosed |
| US-20150299223-A1 | 2-SUBSTITUTED CEPHEM COMPOUNDS | GLAXO GROUP LTD (GB) | 2015-10-22 | — | — | US | disclosed |
| US-20140256697-A1 | CEPHEM DERIVATIVE HAVING CATECHOL GROUP | SHIONOGI & CO., LTD. (JP) | 2014-09-11 | — | — | US | disclosed |
| US-20140114060-A1 | CEPHEM COMPOUND HAVING PYRIDINIUM GROUP | SHIONOGI & CO., LTD. (JP) | 2014-04-24 | — | — | US | disclosed |
| US-20140088302-A1 | NOVEL CEPHEM COMPOUND HAVING CATECHOL OR PSEUDO-CATECHOL STRUCTURE | SHIONOGI & CO., LTD. (JP) | 2014-03-27 | — | — | US | disclosed |
| US-20110190254-A1 | CEPHALOSPORIN HAVING CATECHOL GROUP | SHIONOGI & CO., LTD. (JP) | 2011-08-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (13 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11702431-B2 | Oxo-substituted compound | CYP51A1, OXA1L, O60361 | GABRA1 1353/4885GABRB1 966/4885GABRB2 1342/4885 |
| US-11066425-B1 | Oxo-substituted compound | CYP51A1, OXA1L, O60361 | GABRA1 1353/4885GABRB1 966/4885GABRB2 1342/4885 |
| US-20220162209-A1 | SALICYL-ADENOSINEMONOSULFAMATE ANALOGS AND USES THEREOF | ADSL, SLC35B2, ADORA1 | GABRA1 1989/4885GABRB1 2090/4885GABRB2 2620/4885 |
| US-20140088302-A1 | NOVEL CEPHEM COMPOUND HAVING CATECHOL OR PSEUDO-CATECHOL STRUCTURE | COMT, CMBL, CEP170 | GABRA1 2889/4885GABRB1 1871/4885GABRB2 1765/4885 |
| US-20110190254-A1 | CEPHALOSPORIN HAVING CATECHOL GROUP | NRDC, LUC7L2, NR0B1 | GABRA1 2133/4885GABRB1 1314/4885GABRB2 1507/4885 |
| US-20170281532-A1 | 2 SUBSTITUTED CEPHEM COMPOUNDS | CEP170, CES2, CMBL | GABRA1 3836/4885GABRB1 3329/4885GABRB2 2708/4885 |
| US-20230038124-A1 | NOVEL SUBSTITUTED CONDENSED RING COMPOUND | CYP51A1, HDAC11, MMP9 | GABRA1 2036/4885GABRB1 1219/4885GABRB2 1999/4885 |
| US-20180186814-A1 | TRICYCLIC COMPOUND HAVING SULFINYL OR SULFONYL | SULT1E1, ABCC5, ABCC4 | GABRA1 1800/4885GABRB1 1108/4885GABRB2 1268/4885 |
| US-20140114060-A1 | CEPHEM COMPOUND HAVING PYRIDINIUM GROUP | CEP170, PEPD, CMBL | GABRA1 2314/4885GABRB1 1735/4885GABRB2 1763/4885 |
| US-20140256697-A1 | CEPHEM DERIVATIVE HAVING CATECHOL GROUP | COMT, CEP170, SLC6A3 | GABRA1 3990/4885GABRB1 3567/4885GABRB2 3555/4885 |
| US-20230287009-A1 | OXO-SUBSTITUTED COMPOUND | CYP51A1, OXA1L, O60361 | GABRA1 1353/4885GABRB1 966/4885GABRB2 1342/4885 |
| US-20150299223-A1 | 2-SUBSTITUTED CEPHEM COMPOUNDS | CEP170, ABL1, CEPT1 | GABRA1 3713/4885GABRB1 3124/4885GABRB2 2610/4885 |
| US-10174053-B2 | 2 substituted cephem compounds | CEP170, CES2, CMBL | GABRA1 3836/4885GABRB1 3329/4885GABRB2 2708/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.